"Networking, mentorship, business model, and strategy support expected."

IMBiologics has been officially selected for Johnson & Johnson Innovation's JLABS Korea, as announced on the 29th. JLABS, operated by Johnson & Johnson Innovation, supports member companies in the healthcare sector by providing resources such as development experience, mentorship, partnerships, and venture introductions to accelerate scientific progress.

IMBiologics met all the selection criteria for JLABS Korea, including technological innovation, scientific and technological capabilities, addressing unmet needs, transparency, and ethics. As a result, the company was chosen as an innovative firm for the program.

In June, IMBiologics signed a global technology transfer agreement for the clinical-stage OX40LxTNF bispecific antibody ‘IMB-101’, developed as a treatment for autoimmune diseases, with Navigator Medicines in the U.S. In August, the company also entered into a similar agreement with Hangzhou Zhongmei Huadong Pharmaceutical in China.

IMBiologics is developing autoimmune disease therapeutics and immuno-oncology agents based on its multivalent antibody backbone technology, 'ePENDY' (enhanced/engineered PENtamer boDY) platform, which involves 10 different conjugates.

Jinsoo Jeong, Executive Director of IMBiologics, expressed gratitude for being selected to join the JLABS network, stating, “We are very grateful for this opportunity provided by Johnson & Johnson Innovation. We will focus all our business development efforts to achieve joint research with global pharmaceutical companies and additional technology exports through our JLABS membership.”

"Reporter Sungmin Kim (sungmin.kim@bios.co.kr)"